Recent advances in therapeutic recruitment of mammalian RNAi and bacterial CRISPR-Cas DNA interference pathways as emerging antiviral strategies

详细信息    查看全文

• 作者：Wei-Xin Chin¹Author Vitae ; Swee Kim Ang¹Author Vitae ; Justin Jang Hann Chu¹ ; ² ; ^{miccjh@nus.edu.sg}Author Vitae
• 刊名：Drug Discovery Today
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：22
• 期：1
• 页码：17-30
• 全文大小：712 K
• 卷排序：22

文摘

Developing RNAi and CRISPR-Cas therapeutics for clinical use has been slow. Formulations for cell culture face delivery, toxicity and off-target issues in vivo. This review covers recent advances in clinical RNAi and CRISPR-Cas strategies.